<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/218922-novel-semisynthetic-macrolide-antibodies-of-the-azalide-series by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:25:02 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 218922:NOVEL SEMISYNTHETIC MACROLIDE ANTIBODIES OF THE AZALIDE SERIES</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NOVEL SEMISYNTHETIC MACROLIDE ANTIBODIES OF THE AZALIDE SERIES</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to N&quot;-substituted 9a-N-(N&#x27;-carbamoyl-gamma-aminopropyl), 9a-N-(N-&#x27;4hiocarbamoyl-gamma-aminopropyl), 9a-N-[NH(beta-cyanoethyl)-Nf- carbamoyl-gamma-aminopropyl] and 9a-N-[N&#x27;-((beta-cyanoethyl)-N!- thiocarbamoyl-gamma-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series, of the general formula 1, wherein R represents H or cladinosyl moiety, R&lt;1&gt; represents H or (beta-cyanoethyl moiety, R&lt;2&gt; represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyl)phenyl, 3-phenylpropyl, beta-phenylethyl, ethoxycarbonylmethyl, l-(l-naphtyl)ethyl, 3,4,5-trimethoxyphenyl and 2,4-dichlorophenyl group, and X represents 0 and S, and their acceptable addition salts thereof with inorganic or organic acids, to the process for preparation of their pharmaceutical compositions as well as the use their compositions in the treatment of bacterial infections.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br><br>
Technical field<br>
Int. CI. C 07H 17/08, A6IK 31/71<br>
Technical Problem<br>
The present invention relates to N,!-substituted 9a-N-(N!-carbamoyl-γ--aminopropyl), 9a-N-(N,-thiocarbamoyl-γ-aniinopropyl), 9a-N-[N-β-cyanoethyl)--N'-carbamoyl-γ-aminopropyl] and 9a-N-[N,-(P-cyatioethyl)-N'-thiocarbamoyl-y--aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series having antibacterial activity, of the general formula 1,<br><br><br>
wherein R represents H or cladinosyl moiety, and R1 represents H or P-cyanoethyl group, R2 represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2--(trifluoromethyl)phenyl, 3-phenyIpropyl, P-phenylethyl, ethoxycarbonylmethyl, 1--(l-naphtyl)ethyl, 3,4,5-trimethoxyphenyl and 2,4-dichlorophenyl group, and X represents O or S, to pharmaceutically acceptable addition salts thereof with inorganic or organic acids, to a process for the preparation of the pharmaceutical compositions as well as to the use of the pharmaceutical compositions obtained in the treatment of bacterial infections.<br>
Prior Art<br>
Erithromycin A is a macrolide antibiotic , whose structure is characterized by 14-membered macrolactone  ring having carbonyl group in C-9 position. It was found by McGuire in 1952 [AntibioL Chemother., 2 (1952) 281] and for over 40 years it has been considered as a reliable and effective antimicrobial agent in the treatment of diseases caused by Gram-positive and some Gram-negative microorganisms. However, in an acidic medium it is easily converted into anhydroerythromycin A, an inactiv C-6/C-12  metabolite of a  spiroketal  structure  [P.  Kurath  et  al.,<br><br>
Experientia 27 (1971) 362]it is well-known that spirocyclisation of aglycone ring<br>
of erythromycin A is successfully inhibited by a chemical transformation of C-9<br>
ketones or hydroxy groups in C-6 and/or C-12 position. By the oximation of C-9<br>
ketones [S. Bokic et aL, Tetrahedron Lett 1967: 1945] and by subsequently<br>
modifying the obtained 9(E)-oxime into 9-[0-(2-methoxy-<br>
ethoxy)methyloxime]erithromycin A (ROXITHROMYCIN) [G. S. Ambrieres, Fr.<br>
pat. 2,473,525, 1981] or 9(S)-erithromycylamine [R. S. Egan et al., J. Org. Client.<br>
39 (1974) 2492] or a more complex oxazine derivative thereof, 9-deoxo-ll-deoxy-<br>
-9,11 - {imino[2-(2-methoxyethoxyethylidene]oxy} -9(S)-erythromycin	A<br>
(DIRTTHROMYCIN) [P. Lugar et al., J. Crist. Mol Struct. 9 (1979) 329], novel semisynthetic macrolides were synthetized, whose basic characteristic, in addition to a greater stability in an acidic medium, is a better pharmacokinetics and a long half-time with regard to the parent antibiotic erythromycin A. In a third way for modifying C-9 ketones use is made of Beckmann rearrangement of 9(E)-oxime and of a reduction of the obtained imino ether (G. Kobrehel et al., U.S. Pat. 4,328,334, 1982.) into ll-aza-10-deoxo-10-dihydroerythromycin A (9-deoxo-9a-aza-9a--homoerythromycin A) under broadening the 14-member ketolactone ring into a 15-member azalactone ring. By reductive N-methylation of 9a-amino group according to Eschweiler-Clark process (G. Kobrehel et al., BE Pat. 892,397, 1982.) or by a preliminary protection of amino group by means of conversion into the coresponding N-oxides and then by alkylation and reduction [G. M. Bright, U.S. Pat., 4,474,768, 1984.] N-methyl-ll-aza-10-deoxo-10-dihydroerythromycin A (9--deoxo-9a-methyl-9a-aza-9a-homoerithromycin A, AZITHROMYCIN) was syntetized, a prototype of azalide antibiotics, which, in addition to a broad antimicrobial spectrum including Gram-negative bacteria and intrcellular microorganisms, are characterized by a specific mechanism of transport to the application site, a long biological half-time and a short therapy period. In EP A 0316128 (Bright G. M. et al.) novel 9a-allyl and 9a-propargyl derivatives of 9--deoxo-9a-aza-9a-homoerythromycin A are disclosed and in U.S. Pat. 4,492,688, from 1985 (Bright G. M.) the synthesis and the antibactertial activity of the corresponding cyclic ethers are disclosed. In the there are further disclosed the syntesis   and   the   activity   spectrum   of   novel   9-deoxo-9a-aza-11 -deoxy-9a-<br><br>
-homoerythromycin A 9a,ll-cyclic carbamates and O-methyl derivatives thereof (G. Kobrehel et aL, /. Antibiot. 46 (1993) 1239-1245).<br>
By reaction of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A with isocyanates or isothiocyanates respectively [N. Kujundzic et al. Croat. Pat. 931480, 1993.], 9a--N-(N'-carbamoyl) and 9a-N-(N'-thiocarbamoyl) derivatives of 9-deoxo-9-dihydro--9a-aza-9a-homoerithromycin A with a certian antibacterial activity are obtained.<br>
According to the known and established Prior Art, N"-substituted 9a-N-(N'--carbamoyl-γ-aminopropyl), 9a-N-(N'-thiocarbamoyl-γ-aminopropyl), 9a-N-PST-(β--cyanoethyl)-N'-carbamoyl-γ-aminopropyl] and 9a-N-[N'-(β-cyanoethyl)-N'--thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a--homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a--homoerithronolide A and pharmaceutical^ acceptable addition salts thereof with inorganic or organic acids, a process for the preparation thereof as well as the preparation methods and use an pharmaceutical preparations have not been disclosed as yet.<br>
It has been found and it is object of the present invention, that N"-substituted 9a-N--(N'-carbamoyl-γ-aminopropyl), 9a-N~(N'-thiocarbamoyl-γ-arninopropyl), 9a-N--[N'-(β-cyanoethyl)-N'-carbamoyl-γ-aminopropyl] and 9a-N-[N1-(β-cyanoethyl)-Nl--thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a--homoerithromycin A and 5~0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a--homoerithronolide A, novel semisinthetic macrolide antibiotic of the azalide series and pharmaceutical^ acceptable addition salts thereof with inorganic or organic acids, may be prepared by reacting 9a-N-(y-aminopropyl) and 9a-N-[N'-(P~ -cyanoethyl)-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a--homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a--homoerithronolide A with isocyanates or isothiocyanates and optionally by reacting the obtained N!,-substituted 9a-N-(N'-carbamoyl-γ-aminopropyl), 9a-N--(N'-thiocarbamoyl-γ-aminopropyl), 9a-N-[N,-(β-cyanoethyl)-Nt-carbamoyl-γ--arninopropyl]     and    9a-N-[Nl-(β-cyanoethyl)-N,-thiocarbamoyl-γ-aminopropyl]<br><br>
derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0--desosaminyl-9-deoxO'9-dihydro-9a-aza-9a-homoerithronolide A with organic and inorganic acids.<br>
Technical Solution<br>
It has been found that novel N"-substituted 9a-N-(N,-carbamoyl-γ-aminopropyl), 9a-N-(N'-thiocarbaraoyl-γ-aminopropyl), 9a-N-[N'-(β-cyanoethyl)-N'-carbamoyl-γ--aminopropyl] and 9a-N-[N,-(β-cyanoethyl)-N'-thiocarbamoyl-γ-aminopropyl] derivatives of 9~deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0--desosarainyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of the general formula 1,<br><br>
wherein R represents H or cladinosyl group, R1 represents H or β-cyanoethyl moiety, R2 represents isoproyl, 1-naphtyl, 2-naphtyl, benzyl, 2--(trifluoromethyl)phenyl, 3-phenylpropyl, β-phenylethyl, ethoxycarbonylmethyl, 1--(l-naphtyl)ethyl, 3,4,5-trimethoxyphenyI and 2,4-dichlorophenyl group, and X represents O or S, and their acceptable addition salts there of with inorganic or organic acids, may be prepared by reacting 9a-N-(Y-aminopropyl) and 9a-N-[N'--(β-cyanoethyl)-γ-aminopropyl]    derivatives    of    9-deoxo-9-dihydro-9a-aza-9a-<br><br>
-homoerithromycin     A     and     5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a--homoerithronolide A general formula 2,<br><br>
wherein R represents H or cladinosyl group and R1 represents H or β-cyanoethyl moiety, with isocyanates or thioisocyanates general formula 3,<br><br>
wherein R  and X have above meanings, in toluene, xylene or some other aprotic solvent, at a temperature 0° to 110°C.<br>
Pharmaceutically acceptable acid addition salts, which also represent an object of present invention, were obtained by reaction N"-substituted 9a-N-(N!-carbamoyl-γ--aminopropyl), 9a-N-(N'-thiocarbamoyl-γ-aminopropyl), 9a-N-[N'-(β-cyanoethyl)-N'--carbamoyl-γ-aminopropyl] and 9a-N-(N'-β~cyanoethyl)-N'-thiocarbamoyl-γ--aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A with an at least equimolar amount of the corresponding inorganic or organic acid such as hydrochloric acid, hydroiodic acid, sulfuric acid, phosphoric acid, acetic acid,<br><br>
trifluoroacetic acid, propionic acid, benzoic acid, benzenesulfonic acid, methane sulfonic acid, laurylsulfonic acid, stearic acid, palmitic acid, succinic acid, ethylsuccinic acid, lactobionic acid, oxalic acid, salicylic acid and similar acid, in a solvent inert to the reaction. Addition salts are isolated by evaporating the solvent or, alternatively, by filtration after a spontaneous precipitation or a precipitation by the addition of a non-polar cosolvent.<br>
N"-Substituted 9a-N-(N'-carbamoyl-γ-aminopropyl), 9a-N-(N,-thiocarbamoyl-γ--aminopropyl), 9a-N-(β-cyanoethy^-N^arbamoyl-γ-aniinopropyl] and 9a-N-[NT--(β-cyanoethy^-N'-thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro--9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a--homoerithronolide A of the general formula 1 and pharmaceutical^ acceptable addition salts with inorganic or organic acids thereof possess an antibacterial activity in vitro*<br>
Minimal inhibitory concentration (MIC) is defined as the concentration which shows 90% growth inhibition, and was determinated by broth dilution methods National Committe for Clinical Laboratory Standards (NCCLS, M7-A2 protocols). Final concentration of test substances were in range from 64 to 0.125 mg/1. MIC levels for all compound were determinated on panel of susceptible and resistant Gram positive bacterial strains (5. aureus, S. pneumoniae and S. pyogenes) and on Gram negative strains (E. coli, H. influenzae, E.faecalis, M. catarrhalis).<br>
It is evident from Table 1 and Table 2 that standard strains are susceptible to newly synthetized compounds of general formula 1. Thus they may be used as therapeutic agents in the treatment of invective diseases in animals, especially mammals and humans, caused by a broad spectrum of Gram-positive and Gram-negative bacteria, mycoplasmas and generally patogenic microorganisms that are susceptible to the compounds of the formula 1. To this purpose the above compounds and pharmaceutically acceptable acid addition salts thereof may be administered orally in usual doses from 0.2 mg/kg body weight daily to about 250 mg/kg/day, most<br><br>
preferably from 0.5-50 mg/kg/day, or parenterally in the form of subcutaneous and intramuscular injections.<br>
Process for the preparation of N"-substituted 9a-N-(Nt-carbamoyl-γ-aminopropyl),<br>
9a-N-(N'-thiocarbamoyI-γ-aminopropyl), 9a'N-[N!-(β-cyanoethyl)-lSβ-carbamoyl-γ--aminopropyl] and 9a-N-[N,-(β-cyanoethyl)-Nl-thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0--desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of this invention is illustrated by the following Examples which should in no way be construed as a limitation of the scope thereof.<br><br>
TABLE   1.  Antibacerial  in  vitro  activity  of novel  N"-substituted  9a-N-(N'-<br>
-carbamoyl-γ-aminopropyl)	and	9a-N-(N'-thiocarbamoyl-γ-aminopropyl)<br>
derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A presented as MIC values in comperison with erythromycin A (Er).<br><br>
TABLE 2. Antibacerial in vitro activity of novel N"-substituted 9a-N-[N'-(β--cyanoethyl)-N'-carbamoyl-γ-aminopropyl] and 9a-N-[N,-(β-cyanoethyl)-NI--thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a--homoerithromycin A presented as MIC values in comperison with erythromycin A (Er).<br><br><br><br><br>
Example 1 9-Deoxo-9-dihydro-9a-N-(N'-isopropyIcarbamoyl--γ-aminopropyI)-9a-aza-9a-<br>
-homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.1 g (1.3 mmol) of isopropylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-(N'-isopropylcarbamoyl-7-aminopropyl)-9a--aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 877.<br>
Example 2<br>
9-Deoxo-9-dihydro-9a-N-[NT-(l-naphtyI)carbamoyI-γ-aminopropyI]-9a-aza-9a--homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.22 g (1.26 mmol) of 1-naphtylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-[N,-(l-naphtyI)carbamoyl-γ-aminopropyl]-9a--aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 961.<br>
Example 3<br>
9-Deoxo-9-dihydro-9a-N-(N,-benzyIcarbamoyI-γ-aminopropyl)-9a-aza-9a--homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9~deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.17 g (1.3 mmol) of benzylisocyanate in 10 ml dry<br><br>
toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol: ammonia= 90 ; : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-(N'-benzylcarbamoyl-γ-aminopropyl)-9a-aza--9a-homoerithromycin A was obtained. MS(ES+)m/z = 925.<br>
Example 4<br>
9-Deoxo-9-dihydro-9a-N-(N'-benzylthiocarbamoyI-γ-aminopropyI)-9a-aza-9a--homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.17 g (1.3 mmol) of benzylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol: ammonia= 90 : : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-(N'-benzyltiocarbamoyl-γ-aminopropyl)-9a--aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 941.<br>
Example 5<br>
9-Deoxo-9-dihydro-9a-N-[N'-(l-naphtyl)thiocarbamoyl-γ-aminopropyI-9a-aza--9a-homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(Y-aminopropyl)-9a--homoerithromycin A and 0.17 g (1.3 mmol) of 1-naphtylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(l-naphtyl)thiocarbamoyl-γ-aminopropyl-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 977.<br><br>
Example 6<br>
9-Deoxo-9-dihydro-9a-N-[N'-(2-trifluoromethyl)phenyIcarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(Y-aminopropyl)-9a--homoerithromycin A and 0.24 g (1.3 mmol) of 2-(trifluoromethyI)phenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride ; methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(2-trifluoromethylphenyl)carbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 979.<br>
Example 7<br>
9-Deoxo-9-dihydro-9a-N-IN,-β-phenylpropyl)thiocarbamoyl-γ-aminopropyIl--9a~aza-9a-homoerithromycin A<br>
A mixture of 1.0 g (L26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.22 g (1.3 mmol) of 3-phenylpropylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : : : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(3--phenylpropyl)thiocarbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 969.<br>
Example 8<br>
9-Deoxo-9-dihydro-9a-N-[N,-(β-phenylethyl)carbamoyI-γ-aminopropyl]-9a-aza--9a-homoerithromycin A<br><br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.21 g (1.3 mmol) of β-phenylethylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol: ammonia= 90 : : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(β-phenylethyl)carbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 979.<br>
Example 9<br>
9-Deoxo-9-dihydro-9a-N-(N,-ethoxycarbonyImethylcarbamoyI-γ-aininopropyI)--9a-aza-9a-homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.16 g (1.3 mmol) of ethoxycarbonylmethylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-(N'-ethoxy-carbonylmethyicarbamoyl-γ-aminopropyl)-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 921.<br>
Example 10<br>
9-Deoxo-9-dihydro-9a-N-{N,-[l-(l-naphtyl)ethylcarbamoyI-γ-aminopropyl}-9a--aza-9a-homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.25 g (1.3 mmol) of l-(l-naphtyl)ethylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on<br><br>
sillica gel  column  using  the  solvent system  methylene-chloride  :  methanol   ; : ammonia= 90 :  9  :  1.5, pure 9-deoxo-9-dihydro-9a-N-{N,-[l-(l-naphtyl)ethyl carbamoyl-γ-aminopropyl}-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 989.<br>
Example 11<br>
9-Deoxo-9-dihydro-9a-N-[N'-(3,4,5-trimethoxyphenyl)carbamoyI-γ--aminopropyl]-9a-aza-9a-homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9niihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.26 g (1.3 mmol) of 3,4,5-trimethoxyphenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(3,4,5--trimethoxyphenyl)carbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained.	MS(ES+)m/z=100L<br>
Example 12<br>
9-Deoxo-9-dihydro-9a-N-[N,-(2-naphtyI)carbamoyi-γ-aminopropyl]-9a-aza-9a--homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.23 g (1.3 mmol) of 2-naphtylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 :<br><br>
: 9 : L5/pure9-deoxo-9-dihydro-9a-N-[N'-(2-naphtyl)cait)amoyl-γ-aminopropyll-9a--aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 961.<br>
Example 13<br>
9-Deoxo-9-dihydro-9a-N-IN'-(2,4-dichIorophenyI)carbamoyI-γ-aminopropyl]-9a--aza-9a-homoerithromycin A<br>
A mixture of 1.0 g (1.26 mmol) 9-deoxo-9-dihydro-9a-aza-9a-(y-aminopropyl)-9a--homoerithromycin A and 0.23 g (13 mmol) of 2,4-dichIorophenyIisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(2,4--dichlorophenyl)carbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 979.<br>
Example 14<br>
5-0-DesosaniinyI-9-deoxo-9-dihydro-9a-N-(N'-isopropylcarbamoyl'y--aminopropyl)-9a-aza-9a-homoerithronoIide A<br>
A mixture of 1.0 g (1.57 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(y--aminopropyl)-9a-aza-homoerithronolide A and 0.13 g (1.57 mmol) of isopropylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-0-desosaminyl-9--deoxo-9-dihydro-9a-N-(N'-isopropylcarbamoyI-γ-aminopropyl)-9a-aza-9a--homoerithronolide A was obtained. MS(ES+)m/z = 719.<br><br>
Example 15<br>
5-O-Desosaminyl-β-deoxo-β-dihydro-Pa-N-tN'-(1-naphtyl)carbamoyl-β--aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 1.0 g (1.57 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(y--anainopropyl)-9a-aza-homoerithronolide A and 0.13 g (1.57 mmol) of 1--naphtylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride ; methanol : ammonia= 90 : 20 : 1.5, pure 5-0-desosaminyl-9--deoxo-9-dihydro-9a-N-[N'-(l-naphtyl)carbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithronolide A was obtained. MS(ES+)m/z = 803.<br>
Example 16<br>
5-0-DesosaminyI-9-deoxo-9-dihydro-9a-N-(N,-benzyIcarbamoyI-γ--aminopropyl)-9a-aza-9a-homoerithronolide A<br>
A mixture of 1.0 g (1.57 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(y--aminopropyl)-9a-aza-homoerithronolide A and 0.21 g (1.57 mmol) of benzyhsocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene--chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-0-desosaminyl-9-deoxo-9--dihydro-9a-N-(N'-benzylcarbamoyl-γ-aminopropyI)-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 767.<br>
Example 17<br>
5-O-Desosaminyl)-deoxo-9-dihydro-9-N-(N'-benzylthiocarbamoyl-γ--aminopropyI)-9a-aza-9a-homoerithronoIide A<br><br>
A mixture of 1.0 g (1.57 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.24 g (1.57 mmol) of benzylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-0-desosaminyl-9--deoxo-9Hiihydro-9a-N-(N'-benzylthiocarbamoyl-γ-aininopropyl)-9a-aza-9a--homoerithronolide A was obtained. MS(ES+)m/z = 783.<br>
Example 18<br>
5-0-DesosaminyI-9-deoxo-9-dihydro-9a-N-[N'-(l-naphtyl)thiocarbamoyI-γ--aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 1.0 g (1.57 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.29 g (1.57 mmol) of 1--naphtylisothiocyanate in 10 ml dry toluene was .stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-0-desosaminyl-9--deoxo-9-dihydro-9a-N-[N'-(l-naphtyl)thiocarbamoyl-7-aminopropyl]-9a-aza-9a--homoerithronolide A was obtained. MS(ES+)m/z = 819.<br>
Example 19<br>
S-O-Desosaminyl^-deoxo-β-dihydro^a-N-CN'^l--(trifluoromethyl)phenylcarbamoyI)-γ-aminopropyl]-9a-aza-9a -homoerithronolide A<br><br>
A mixture of 1.0 g (1.57 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronoIide A and 0.30 g (1.57 mmol) of 2--(trifluoromethyl)phenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-0--desosaminyl-9-deoxo-9-dihydro-9a-N-[N,-(2-(trifluoromethyl)phenylcarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 821.<br>
Example 20<br>
S-O-Desosaminyl-β-deoxo-9-dihydro-Pa-N-[N'-(3-phenylpropyl)thiocarbamoyl--γ-aminopropyl]-9a-aza-9a-homoerithronoIide A<br>
A mixture of 1.0 g (1.57 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.28 g (1.57 mmol) of 3--phenylpropylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-0-desosaminyl-9--deoxo-9-dihydro-9a-N-|N,--(3'phenylpropyl)thiocarbamoyl-γ-aminopropyl]-9a-aza--9a-homoerithronolide A was obtained. MS(ES+)m/z = 811.<br>
Example 21<br>
5-0-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(β-phenylethyl)thiocarbamoyl-γ--aminopropyI]-9a-aza-9a-homoerithronoIide A<br>
A mixture of 1.0 g (1.57 mmol) 5-0-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyI)-9a-aza-homoerithronolide A and 0.26 g (1.57 mmol) of β--phenylethylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered,<br><br>
wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[N,-(β-phenylethyl)thiocarbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithronolide A was obtained. MS(ES+)m/z = 797.<br>
Example 22<br>
5-O-Desosaniinyl-9-deoxo-9-dihydro-9a-N-(N'-ethoxykarbonylmethyI-carbamoyl-γ-aminopropyl)-9a-aza-9a-homoerithronolide A<br>
A mixture of 1.0 g (1.57 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.20 g (1.57 mmol) of ethoxykarbonylmethylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : - 20 : 1.5, pure 5-O--desosaminyl-9-deoxo-9-dihydro-9a-N-(N,-ethoxykarbonylmethylcarbamoyl-γ--aminopropyl)-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 763.<br>
Example 23<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-[Nl-(2-naphtyl)carbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 1.0 g (1.57 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.27 g (1.57 mmol) of 2--naphtylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 ; 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[N'-(2-naphtyl)carbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithronolide A was obtained.<br><br>
MS(ES+)m/z = 803.<br>
Example 24<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-{N,-[l-(l-naphtyI)ethyl]carbamoyI-γ--aminopropyl}-9a-aza-9a-homoerithronoIide A<br>
A mixture of 1.0 g (L57 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.31 g (1.57 mmol) of 1 -(1 --naphtyl)ethylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 ; 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N- {N!-[ l-(l-naphtyl)ethyl]carbamoyl-γ-aminopropyl} -9a-aza--9a-homoerithronolide A was obtained. MS(ES+)m/z = 831.<br>
Example 25<br>
5-O-DesosaminyI-9-deoxo-9-dihydro-9a-N-[N,-(3,4,5-trimethoxyphenyl)-carbamoyI-γ-aminopropyI]-9a-aza-9a-homoerithronolide A<br>
A mixture of 1.0 g (1.57 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ-~aminopropyl)-9a-aza-homoerithronolide A and 0.31 g (1.57 mmol) of 3,4,5--trimethoxyphenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-pSf'-(3,4,5-trimethoxyphenyl)carbamoyl-γ-aminopropyl]-9a--aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 843.<br><br>
Example 26<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N!-(2,4-dichlorophenyl)carbamoyl-γ-' -aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 1.0 g (1.57 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.31 g (1.57 mmol) of 2,4-dichlorophenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[N,-(3,4,5-trimethoxyphenyl)carbamoyl-γ-aminopropyl]-9a--aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 821.<br>
Example 27<br>
9-Deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N,-isopropylcarbamoyI-γ--aminopropyI]-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.06 g (0.591 mmol) of isopropylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N-[N'-(β-cyanoethyl)-N,-isopropylcarbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithromycin A was obtained. MS(ES+)m/z = 931.<br>
Example 28<br>
9-Deoxo-9-dihydro-9a-N-[N-(β-cyanoethyI)-N,-(l-naphtyl)carbamoyI-γ--aminopropyI]-9a-aza~9a-homoerithromycin A<br><br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.11 g (0.591 mmol) of 1--naphtylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol: ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N-[N,-(β-cyanoethyl)-N,-(l-naphtyl)carbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithromycin A was obtained. MS(ES+)m/z =.<br>
Example 29<br>
9-Deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N,-benzylcarbamoyl-γ--aminopropyI]-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.08 g (0.591 mmol) of benzylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene--chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-N-[N'-(β--cyanoethyl)-N,-benzylcarbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 931.<br>
Example 30<br>
9-Deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N'-benzyIthiocarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.09 g (0.591 mmol) of benzylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered,<br><br>
wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N-[N,-(β-cyanoethyl)-Nt-benzylthiocarbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithromycin A was obtained. MS(ES+)m/z = 995.<br>
Example 31<br>
9-Deoxo-9-dihydro-9a-N-[Nl-(β-cyanoethyl)-N,-(l-naphtyl)thiocarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.12 g (0.591 mmol) of 1--naphtylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N-[NHβ-cyanoethyl)-N,-(l-naphtyl)thiocarbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithromycin A was obtained. MSOES^m/z = 1029.<br>
Example 32<br>
9-Deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N'-(2-(trifluoromethyI)phenyl)carbamoyI-γ-aminopropyI]-9a-aza-9a--homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.08 g (0.591 mmol) of 2--(trifluoromethyl)phenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-<br><br>
-dihydro-9a-N-[N,-(β-cyanoethyl)-N,-(2-(trifluoromethyl)phenyl)carbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 1033.<br>
Example 33<br>
9-Deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyI)-N'-(3-phenylpropyl)carbamoyl-7--aminopropyl]-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.10 g (0.591 mmol) of 3--phenylpropylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chioride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N-[N'-(β-cyanoethyl)-N'-(3-phenylpropyl)carbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithromycin A was obtained. MS(ES+)m/z = 1022.<br>
Example 34<br>
9-Deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N'-(β-phenylethyI)thiocarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.10 g (0.591 mmol) of β--phenylethylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chioride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N-[N,-(β-cyanoethyl)-N,-(β-phenylethyl)thiocarbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithromycin A was obtained. MS(ES*)m/z = 1008.<br><br>
Example 35<br>
9-Deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-N,-ethoxycarbonylmethyI-carbamoyl]-γ-aminopropyl]-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.10 g (0.591 mmol) of ethoxycarbonylmethylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9--dihydro-9a-N-PST!-(β-cyanoethyl)-N!-ethoxycarbonylmethylcarbamoyl]-7--aminopropyl]-9a-aza-9a-homoerithromycin A was obtained. MS(ES+)m/z = 974.<br>
Example 36<br>
9-Deoxo-9-dihydro-9a-N-{Nl-(β-cyanoethyI)-N,-[l-(l-naphtyI)ethyI]carbamoyl-γ--aminopropyl}-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-((i-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.11 g (0.591 mmol) of 1-(1--naphtyl)ethyIisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N-{N,-(β-cyanoethyl)-N,-[l-(l-naphtyl)ethyl]carbamoyl-γ-aminopropyl}-9a-aza-9a--homoerithromycin A was obtained. MS(ES+)m/z=1042.<br>
Example 37<br>
9-Deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyI)-N'-(3,4,5-<br>
-trimethoxyphenyI)carbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithromycin A<br><br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-7-aminopropyl]-9a-aza-9a-homoerithromycin A and 0.12 g (0.591 mmol) of 3,4,5-trimethoxyphenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N-[N'-(β-cyanoethyO-N'-(3,4,5-tximethoxyphenyl)-carbamoyl-γ-aminopropyll^a--aza-9a-homoerithromycin A was obtained. MS(ES+)m/z=1053.<br>
Example 38<br>
9-Deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N,-(2-naphtyI)carbamoyI-γ--aminopropyI]-9a-aza-9a4iomoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.11 g (0.591 mmol) of 2-naphtylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a--N"P^l-(β-cyanoethyl)-N,-(2-naphtyl)carbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithromycin A was obtained. MS(ES+)m/z = 1014.<br>
Example 39<br>
9-Deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyI)-N,-(2,4-dichlorophenyl)carbamoyl--7-aniinopropyI]-9a-aza-9a-homoerithromycin A<br>
A mixture of 0.5 g (0.591 mmol) 9-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-γ--aminopropyl]-9a-aza-9a-homoerithromycin A and 0.11 g (0.591 mmol) of 2--naphtylisocyanate in  10 ml  dry toluene was stirred for 30 minutes  at room<br><br>
temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol: ammonia= 90 : 9 : 1.5, pure 9-deoxo-9-dihydro-9a-«N-[N-(β-cyanoethyl)-N,-(2,4-dichlorophenyl)carbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithromycin A was obtained. MS(ES+)m/z = 1033.<br>
Example 40<br>
S-O-Desosaminyl-β-deoxo-β-dihydro-Pa-N-[N'-(β-cyanoethyO-N1--isopropyIcarbamoyl-γ-aminopropyI]-9a-aza-9a-homoerithronoUde A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza~homoerithronolide A and 0.06 g (0.728 mmol) of isopropylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-N!-isopropylcarbamoyI-γ-aminopropyl]--9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 771.<br>
Example 41<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyI)-N'-(l-<br>
-naphtyl)carbamoyI-γ-aminopropyl]-9a-aza-9a"homoerithronolideA<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.12 g (0.728 mmol) of 1--naphtylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered,<br><br>
wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol; ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-β-dihydro-Pa-N-[N'-Cβ-cyanoethyl)-N-Cl-naphtyl)carbamoyl-γ-aminopropyl]--9a-aza-9a-homoerithronolide A was obtained. MSCES^m/z = 855.<br>
Example 42<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N'--benzylcarbamoyI-γ-aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 0,5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.10 g (0.728 mmol) of benzylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene--chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9-deoxo-9-^ihydro-9a-N-|TSI,-(P^yanoethyl)-N,-benzylcarbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithronolide A was obtained. MS(ES+)m/z = S19.<br>
Example 43<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N'--benzylthiocarbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.11 g (0.728 mmol) of benzylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9-deoxo-9-Hiihydro-9a-N-[N,-(β-cyanoethyl)-NI-benzylthiocarbamoyl-γ-aminopropyl]-9a-aza--9a-homoerithronolide A was obtained.<br><br>
MS(ES)m/z = 835.<br>
Example 44<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-CN'-(β-cyanoethyO-N'-(1--naphtyl)thiocarbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithronoIide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.14 g (0.728 mmol) of 1--naphtylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-N'-(l-naphtyl)thiocarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 855.<br>
Example 45<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N,-(2--(trifluoromethyI)phenyl)carbamoyl-γ-aminopropyl]-9a-aza-9a--homoerithronolide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a~aza-homoerithronolide A and 0.14 g (0.728 mmol) of 2--(trifluoromethyl)phenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O--desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-N!-(2-(trifluoromethyl)-phenylcarbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 873.<br><br>
Example 46<br>
5-O-Desosaminyl--9-deoxo--9-dihydro-9a-N-IN'-(β-cyanoethyO-N'-(3---phenylpropyI)thiocarbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.13 g (0.728 mmol) of 3--phenylpropylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxO'9-dihydro-9a-N-[N!-(β-cyanoethyl)-N,-(3-phenylpropyl)thiocarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 863.<br>
Example 47<br>
5-O-DesosaminyI-9-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N,-(β--phenylethyI)thiocarbamoyI-γ-aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(7--aminopropyl)-9a-aza-homoerithronolide A and 0.12 g (0.728 mmol) of β--phenylethylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-N'-(β-phenylethyl)thiocarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z =.<br>
Example 48<br><br>
5-O-Desosaminyl-β-deoxo-β-dihydro-^a-N-tN'-Cβ-cyanoethyO-N'-ethoxγ-carbonylmethylcarbamoyl-γ-aminopropyI]-9a-aza-9a-homoerithronolide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronoIide A and 0.09 g (0.728 mmol) of β--phenylethylisothiocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-N*-ethoxycarbonylmethylcarbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)ro/z = S15.<br>
Example 49<br>
5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-[N'-(β-cyanoethyl)-N'-(2--naphtyl)carbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.12 g (0.728 mmol) of 2--naphtylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[Nt-(β-cyanoethyl)-N,-(2-naphtyl)carbamoyl-γ-aminopropyl]--9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 855.<br>
Example 50<br>
5-O-Desosaminyl-9-deoxo-9--dihydro-9a-N-[N-β-cyanoethyl)-N'[1-(1--naphtyl)ethylcarbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithronolide A<br><br>
A mixture of 0.5 g (0.72S mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.15 g (0.728 mmol) of 1-(1--naphtyl)ethylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 ; 1.5, pure 5-O-desosaminyl-9-<br>
-deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N,-[l-(l-naphtyl)ethyl)carbamoyl-γ--aminopropyl]~9a-aza-9a-homoerithronolide A was obtained.<br>
MS(ES+)m/z = 883.<br>
Example 51<br>
5-O-Desosaminyl-β-deoxo-β-dihydro^a-N-tN'-(β-cyanoethy)-N'-(3,4,5--trimethoxyphenyI)carbamoyI-γ-aminopropyI]-9a-aza-9a-homoerithronoIide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.14 g (0.728 mmol) of 3,4,5--trimethoxyphenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[N,-(β-cyanoethyl)-N'-(3,4,5-trimethoxyphenyI)carbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithronolide A was obtained. MS(ES+)m/z = 895.<br>
Example 52<br>
5-O-DesosaminyI-9-deoxo-9-dihydro-9a-N-[Nl-(β-cyanoethyl)-N,-(2,4--dichlorophenyI)carbamoyl-γ-aminopropyl]-9a-aza-9a-homoerithronolide A<br>
A mixture of 0.5 g (0.728 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-(γ--aminopropyl)-9a-aza-homoerithronolide A and 0.14 g (0.728 mmol) of 2,4--dichlorophenylisocyanate in 10 ml dry toluene was stirred for 30 minutes at room<br><br>
temperature to complete the reaction. The crystalls of the crude product were filtered, wherefrom by chromatography on sillica gel column using the solvent system methylene-chloride : methanol : ammonia= 90 : 20 : 1.5, pure 5-O-desosaminyl-9--deoxo-9-dihydro-9a-N-[Nt-(β-cyanoethyl)-N,-(2,4-dichlorophenyl)carbamoyl-γ--aminopropyl]-9a-aza-9a-homoerithronolide A was obtained.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
WE CLAIM:<br>
1.	A compound of formula 1,<br><br>
wherein R represents H or cladinosyl moiety,<br>
R1 represents H or β-cyanoethyI moiety,<br>
R2 represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyl)phenyl, 3-phenyIpropyl, p-phenylethyl, ethoxycarbonyl-methyl, l-(I-naphtyl)ethyl, 3,4,5-trimethoxyphenyl or a 2,4-dichlorophenyl group, and<br>
X represents O or S,<br>
and pharmaceutically acceptable addition salts thereof.<br>
2.	The compound according to claim 1, wherein R1 represents H, R2 represents<br>
isopropyl group and X is O.<br>
3.	The compound according to claim 1, wherein R1 represents H, and R represents 1-naphthyl group and X is O.<br>
4.	The compound according to claim  1, wherein R1  represents H, and R represents 2-naphthyl group and X is O.<br><br>
5.	The compound according to claim  1, wherein R1  represents H, and R2 represents benzyl group and X is O.<br>
6.	The compound according to claim  1, wherein R1 represents H, and R2 represents 2-(trifluoromethyl) phenyl group and X represents O.<br>
7.	The compound according to claim  1, wherein R1  represents H, and R2 represents 3-phenylpropyl group and X is S.<br>
8.	The compound according to claim  1, wherein Rl represents H, and R2 represents p-phenylethyl group and X is S.<br>
9.	The compound according to claim  1, wherein R1  represents H, and R2 represents ethoxycarbonylmethyl group and X is O.<br>
10.	The compound according to claim  1, wherein R1 represents H, and R2 represents l-(l-naphtyl) ethyl group and X is O.<br>
11.	The compound according to claim  1, wherein R   represents H, and R represents 3,4,5-trimethoxyphenyl group and X is O.<br>
12.	The compound according to claim  1, wherein R   represents H, and R represents 2,4-dichlorophenyl group and X is O.<br>
13.	The compound according to claim  1, wherein R   represents H, and R represents benzyl group or 1-naphtyl group and X is O.<br>
14.	The compound according to claim 1, wherein R1 represents   β-cyanoethyl group, R2 represents 3- represents 3-phenylpropyl group and X is S.<br><br>
15.	The compound according to claim 1, wherein R1 represents   β-cyanoethyl group, R2 represents β-phenylethyl group and X is S.<br>
16.	The compound according to claim 1, wherein R1 represents   β-cyanoethyl group, R2 represents 2,4-dichlorophenyl group and X is O.<br>
17.       A process for the preparation of a compound as claimed in claim 1    1 characterized in that compound of formula 2,<br><br>
wherein R represents H or a cladinosyl group and<br>
R represents H or a p-cyanoethyl group<br>
is reacted with isocyanate or isothiocyanate of formula 3<br><br>
wherein R2 represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyI) phenyl, 3-phenylpropyl, β-phenylethyl, ethoxycarbonyl-methyl, 1-(1-naphtyl)ethyl, 3,4,5-trimethoxyphenyl or a 2,4-dichlorophenyl group, and<br>
X represents O or S,<br>
in toluene, xylene or some others aprotic solvent at a temperature 0° -110° C<br>
18.	The process according to claim 17, wherein the components are farther related<br>
with inorganic or organic acid.<br>
19.	A pharmaceutical  composition comprising a pharmaceutically  acceptable<br>
carrier and an antibacterially effective amount of the substance according to claim 1.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1IGFic3RyYWN0IGR1cGxpY2F0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">1551-chenp-2005 abstract duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1IGNsYWltcyBkdXBsaWNhdGUucGRm" target="_blank" style="word-wrap:break-word;">1551-chenp-2005 claims duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1IGRlc2NyaXB0aW9uIChjb21wbGV0ZSkgZHVwbGljYXRlLnBkZg==" target="_blank" style="word-wrap:break-word;">1551-chenp-2005 description (complete) duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWNvcnJlc3BvbmRuZWNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-correspondnece-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWNvcnJlc3BvbmRuZWNlLXBvLnBkZg==" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-correspondnece-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWRlc2NyaXB0aW9uKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWZvcm0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LWZvcm0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU1MS1jaGVucC0yMDA1LXBjdC5wZGY=" target="_blank" style="word-wrap:break-word;">1551-chenp-2005-pct.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="218921-a-body-fluid-testing-device-and-a-test-cassette-for-housing-test-media.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="218923-enantiomers-of-thiophene-hydroxamic-acid-derivatives.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>218922</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1551/CHENP/2005</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>23/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>06-Jun-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>16-Apr-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>07-Jul-2005</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>PLIVA-ISTRAZIVACKI INSTITUT D.O.O</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>BUKVIC KRAJACIC, Mirjana</td>
											<td></td>
										</tr>
										<tr>
											<td>2</td>
											<td>KUJUNDZIC, Nedjeljko</td>
											<td></td>
										</tr>
										<tr>
											<td>3</td>
											<td>BRAJSA, Karmen</td>
											<td></td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07H17/00</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/HR2003/000062</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-12-10</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>P20020991A</td>
									<td>2002-12-12</td>
								    <td>Croatia</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/218922-novel-semisynthetic-macrolide-antibodies-of-the-azalide-series by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:25:03 GMT -->
</html>
